Brain

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

MADRID, Spain and BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical…

5 months ago

De Oro Devices Names Cori Lathan, PhD, as New CEO

Dr. Lathan brings two decades of medical technology with her to drive the health tech startup forwardSAN LUIS OBISPO, CA…

5 months ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas…

5 months ago

Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, welcomes the Federal Circuit’s ruling to lift…

5 months ago

The Government Draws Attention to Swedish Alzheimer’s Research and Together with the Swedish Alzheimer’s Foundation Visit AlzeCure Pharma

STOCKHOLM, SWEDEN / ACCESSWIRE / January 17, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

5 months ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

5 months ago

Day One Announces Two New Appointments to Board of Directors

BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage…

5 months ago

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

BASKING RIDGE, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

5 months ago

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function,…

5 months ago

DiagnaMed Announces Pilot Launch of CERVAI™ Brain Health AI Solution

CERVAI™ Brain Health CERVAI™ Brain Health TORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”)…

5 months ago